There is no doubt a regulated market for access to medicinal cannabis is safer, but if cannabis-based products were allowed to bypass efficacy trials, there’s a potential cost to patient safety.
- Associate Professor, University of Otago
Contact John for
- General
- Media request
- Speaking request
- Consulting / Advising
- Research collaboration
- Research supervision
- Article Feed
- Joined
